Welcome to our dedicated page for Seer news (Ticker: SEER), a resource for investors and traders seeking the latest updates and insights on Seer stock.
Seer, Inc. develops and commercializes research-use proteomics products centered on its Proteograph Product Suite. The suite integrates proprietary engineered nanoparticles, optimized consumables, automation instrumentation and analytical software for proteomic analysis in research laboratories, academic institutions and biopharmaceutical settings.
SEER news commonly covers financial results and outlook, Proteograph adoption, research collaborations in multi-omic and population-scale studies, intellectual-property developments involving particle-based protein enrichment, and commercial leadership changes. Company updates also include governance and shareholder matters, including board responses to unsolicited proposals, director nominations, rights plans and other capital-structure actions.
Seer, Inc. (Nasdaq: SEER) reported a significant increase in revenue for the full year 2021, totaling $6.6 million, driven by the successful launch of the Proteograph Product Suite. The fourth quarter alone saw revenue of $3.1 million, up from $336 thousand in Q4 2020. However, the company faced a net loss of $19.7 million in the fourth quarter and $71.2 million for the full year. For 2022, Seer anticipates revenue of $14.0 million to $16.0 million while increasing investments in commercial and R&D activities.
Seer, a life sciences company specializing in proteomics, has announced its virtual participation in the Cowen 42nd Annual Health Care Conference scheduled for March 8, 2022. The company's management will engage in a fireside chat at 11:50 a.m. Pacific Time. Interested investors can access a live webcast on Seer’s investor website, with an archived replay available afterward. Seer’s Proteograph Product Suite enables deep proteomic analysis efficiently and is designed for research use only, aiming to enhance laboratory capabilities.
Seer Inc. (NASDAQ: SEER) will release its financial results for Q4 and full year 2021 on February 28, 2022, after market close. A conference call with management will follow at 1:30 PM PT / 4:30 PM ET, available via a live webcast on Seer's investor website. Seer specializes in proteomics, offering the Proteograph Product Suite, which comprises engineered nanoparticles and software for comprehensive proteomic analysis. The suite aims to enhance research efficiency, though it is not intended for diagnostic use.
Seer Inc. (NASDAQ: SEER) has officially launched the Proteograph Product Suite, which promises revolutionary advancements in proteomics, akin to next-generation sequencing in genomics. The suite employs proprietary engineered nanoparticles, enabling rapid and unbiased proteomics analysis. Seer has secured multiple orders for this product and initiated its Centers of Excellence program, partnering with leading service providers globally to facilitate the technology's adoption. Key partners include Biodesix and Discovery Life Sciences, enhancing service accessibility in major geographies.
Seer Inc. (NASDAQ: SEER), SCIEX, and Discovery Life Sciences have formed the Proteogenomics Consortium to enhance proteomics analysis for genomics research. This collaboration aims to analyze over 1 billion peptides annually, enabling the discovery of new protein variants and biomarkers. The Proteograph Product Suite and SCIEX ZenoTOF 7600 will provide deep, unbiased proteomics capabilities. The consortium is positioned to accelerate research in human health and disease, significantly expanding proteomic studies across various cohorts.
Seer Inc. (NASDAQ: SEER) has announced the broad commercial release of its Proteograph Product Suite, which facilitates unbiased and rapid proteomics. The product suite has garnered multiple orders and includes engineered nanoparticles, automated instrumentation, and software for deep proteomics studies. Seer's new Centers of Excellence program aims to accelerate the adoption of this technology by partnering with leading service providers worldwide. These developments position Seer as a leader in innovative proteomics solutions, enhancing research capabilities across various regions.
Seer, Inc. (Nasdaq: SEER) will participate in the 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022. The management team is scheduled to present at 8:15 a.m. Pacific Time and will hold a Q&A session. A live webcast will be available on Seer's investor website, with an archived replay accessible afterward.
Seer specializes in developing products for proteomic analysis, including the Proteograph™ Product Suite, designed for deep and unbiased analysis in a streamlined manner. This product is intended for research use only.
Seer, Inc. (Nasdaq: SEER) has appointed Meeta Gulyani to its Board of Directors. Gulyani, currently Executive Vice President at Merck KGaA, brings extensive experience in life sciences. Her leadership is expected to support Seer's mission in proteomics, which aims to unlock new insights in healthcare. Gulyani has held significant roles at Roche and possesses a strong background in strategy, business development, and transformation. Seer's Proteograph Product Suite is at the forefront of proteomic analysis, enhancing research capabilities in various laboratories.
Seer, a life sciences company listed on Nasdaq as SEER, announced its participation in the Piper Sandler 33rd Annual Virtual Healthcare Conference. A pre-recorded presentation will be available online starting November 22, 2021. Additionally, Seer will conduct investor meetings on December 1 and 2, 2021. The company is focused on its Proteograph Product Suite, designed for efficient and deep proteomic analysis, accessible to many laboratories. The suite is for research use only and not intended for diagnostic procedures.
Seer, Inc. reported third-quarter 2021 revenues of $2.2 million, a significant increase from $72,000 in Q3 2020, driven by the Proteograph Product Suite. Product-related revenue reached $1.6 million, with a gross profit of $1.2 million and a gross margin of 54%. However, the company's operating expenses surged to $19.6 million, resulting in a net loss of $18.4 million. As of September 30, 2021, Seer held approximately $506.6 million in cash and investments. The company is on track for a Broad Release of its product in early 2022.